Decision support system for macular oedema due to retinal vein occlusion (RVO)

Background: The vision loss caused by Macular Oedema (ME) due to retinal vein occlusion can have severe consequences on those affected by condition including long-term visual disability. Methodology: Based on the best available scientific evidence for clinical approach to ME including several clinical trials, we present practical treatment recommendations. Results : Identification & medical management of modifiable systemic risk factors, and recognition and management of sight-threatening complications form the principal line of management of ME due to RVO. Conclusion : Taking into account recent advances in diagnostic methods and management options, we aim to provide ophthalmologists with guidelines for clinical practice to maximize outcomes. Current novel technology of intraocular drug delivery systems (DDS) and, non-biodegradable /biodegradable implants /inserts combined with future improvement in efficacy and/or reduced dosing of currently available drugs will add new horizons in treatment modalities for ME.